Netherlands· NL-d80c8c8b14f7

Yomesan 500 mg, kauwtabletten

A niclosamide product containing niclosamide, registered in Netherlands by Bayer B.V.. The same ATC class is registered in 7 of our 19 countries.

ATC P02DA01

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about niclosamideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Niclosamide is registered in 7 of 19 countries.

Countries holding a registration under ATC P02DA01 (niclosamide), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
4 of them publish a price we can compare per daily dose

Search niclosamide products by name

Niclosamide · ATC P02DA01

7 / 19 countries

Belgiumprice
Finlandprice
Germany
Italyprice
Netherlands
Norwayprice
United Kingdom

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of niclosamide costs, country by country.

Normalised to the WHO defined daily dose (2 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Niclosamide · price per daily dose (2 g)

USD · FX 28 Sept 2026

IT Italy$3.23

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: NICLOSAMIDE
Manufacturer: Bayer B.V.
Country: Netherlands (NL)
ATC code: P02DA01
ATC class: Niclosamide
Defined daily dose: 2 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
00886

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for niclosamide.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check niclosamide against other medicines How interaction checks work

Niclosamide · interactions on record

7 records

1 severe
6 moderate

Most severe, free to view

TizanidineM03BX02severe
AlosetronA03AE01moderate
DuloxetinG04BX18moderate
BendamustineL01AA09moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Niclosamide in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All niclosamide products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

Belgium · Yomesan
Germany · Yomesan
Italy · Yomesan
Luxembourg · Yomesan
Sweden · Yomesan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/8fa79b28-ed67-4244-abd3-0b0c09c6467a
GET /v1/drugs/8fa79b28-ed67-4244-abd3-0b0c09c6467a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kauwtablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h00886_smpc.pdf",
  "strength": null,
  "atc_label": "Niclosamide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg00886",
  "excipients": [
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL",
    "NATRIUMLAURILSULFAAT",
    "POVIDON (E 1201)",
    "SACCHAROIDE NATRIUM X-WATER (E 954)",
    "TALK (E 553b)",
    "VANILLINE"
  ],
  "substances": [
    "NICLOSAMIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h00886.pdf",
  "authorised_at": "1990/05/20",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "00886",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about niclosamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console